Goldman Sachs’s Translational Development Acquisition Corp TDAC Stock Holding History
Bought
Maintained
Sold
Other funds holding TDAC
Goldman Sachs's TDAC Position: Q2 2026 in Review
Goldman Sachs reduced its Translational Development Acquisition Corp (TDAC) stake by 11% in Q2 2026, selling an estimated $451K and leaving 342,787 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4165.
Goldman Sachs first reported a position in TDAC in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.07M in Q1 2026. 35 funds tracked by Wall St. Rank hold TDAC as of Q2 2026.
- Goldman Sachs held 342,787 shares of Translational Development Acquisition Corp worth $3.66M as of Q2 2026.
- Goldman Sachs sold 42,223 Translational Development Acquisition Corp shares in Q2 2026, an estimated $451K.
- Translational Development Acquisition Corp made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4165 holding.
- Goldman Sachs first reported a position in Translational Development Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
- Goldman Sachs's Translational Development Acquisition Corp position peaked at $4.07M in Q1 2026.
- 35 funds tracked by Wall St. Rank held Translational Development Acquisition Corp as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.